Author pages are created from data sourced from our academic publisher partnerships and public sources.
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
BACKGROUND Wild type RAS (RAS-wt) status is predictive of the activities of the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (C) and panitumumab (P). We examined the… Expand
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
INTRODUCTION The prognosis of advanced/recurrent cervical cancer patients is generally poor with 1-year survival ranging between 15 and 20%. Cisplatin (CDDP) based treatments are considered the most… Expand
Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies.
The combinations of radiotherapy (RT) plus chemotherapy (CTRT) with cisplatin or, alternatively, RT plus cetuximab (RT+CET), are the treatments of choice for locally advanced squamous cell carcinoma… Expand
FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer: A Meta-Analytical Review of Published Studies
Objective The use of neoadjuvant chemotherapy can enable surgical resection of borderline resectable or unresectable pancreatic cancer (PC). The aim of this study was to evaluate the effectiveness of… Expand
Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis.
PURPOSE Early tumour shrinkage (ETS), defined as a reduction of at least 20% in tumour size at first reassessment, has been recently investigated retrospectively in first-line trials of metastatic… Expand
Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
- F. Petrelli, A. Coinu, M. Cabiddu, M. Ghilardi, I. Vavassori, S. Barni
- European urology
- 1 February 2014
CONTEXT Neoadjuvant chemotherapy before radical cystectomy (RC) is the preferred initial option for muscle-invasive bladder cancer (BCa). As in rectal and breast cancer, pathologic downstaging is… Expand
A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer
- F. Petrelli, A. Coinu, V. Lonati, S. Barni
- International Journal of Colorectal Disease
- 1 April 2015
BackgroundCurrent guidelines support the use of adjuvant chemotherapy (CT) following neoadjuvant chemoradiotherapy (CTRT) and surgery to treat rectal cancer, although clinical trials have provided… Expand
Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials
- F. Petrelli, A. Coinu, M. Cabiddu, M. Ghilardi, V. Lonati, S. Barni
- Breast Cancer Research and Treatment
- 17 July 2013
Five years of adjuvant hormonal therapy is the standard of care in early breast cancer (BC) expressing oestrogen receptors (ER+). Prolonged duration of adjuvant endocrine therapy is implemented to… Expand
Platinum rechallenge in patients with advanced NSCLC: a pooled analysis.
- F. Petrelli, A. Coinu, M. Cabiddu, M. Ghilardi, M. Ardine, S. Barni
- Lung cancer
- 1 September 2013
INTRODUCTION The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets.… Expand
Surveillance or Adjuvant Treatment With Chemotherapy or Radiotherapy in Stage I Seminoma: A Systematic Review and Meta-Analysis of 13 Studies.
OBJECTIVE Testicular stage I seminoma has a remarkable cure rate with orchiectomy alone. The benefit of adjuvant therapy is questionable, and a direct comparison with active surveillance is lacking.… Expand